Regulation of cancer epigenomes with a histone-binding synthetic transcription factor

David B. Nyer, Rene M. Daer, Daniel Vargas, Caroline Hom, Karmella Haynes

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Chromatin proteins have expanded the mammalian synthetic biology toolbox by enabling control of active and silenced states at endogenous genes. Others have reported synthetic proteins that bind DNA and regulate genes by altering chromatin marks, such as histone modifications. Previously, we reported the first synthetic transcriptional activator, the "Polycomb-based transcription factor" (PcTF) that reads histone modifications through a protein-protein interaction between the polycomb chromodomain motif and trimethylated lysine 27 of histone H3 (H3K27me3). Here, we describe the genome-wide behavior of the polycomb-based transcription factor fusion protein. Transcriptome and chromatin profiling revealed several polycomb-based transcription factor-sensitive promoter regions marked by distal H3K27me3 and proximal fusion protein binding. These results illuminate a mechanism in which polycomb-based transcription factor interactions bridge epigenomic marks with the transcription initiation complex at target genes. In three cancer-derived human cell lines tested here, some target genes encode developmental regulators and tumor suppressors. Thus, the polycomb-based transcription factor represents a powerful new fusion protein-based method for cancer research and treatment where silencing marks are translated into direct gene activation.

Original languageEnglish (US)
Article number1
Journalnpj Genomic Medicine
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Histones
Transcription Factors
Histone Code
Chromatin
Neoplasms
Proteins
Synthetic Biology
Genes
Developmental Genes
Gene Expression Profiling
Genetic Promoter Regions
Protein Binding
Epigenomics
Transcriptional Activation
Lysine
Genome
Cell Line
DNA
Research

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Genetics(clinical)

Cite this

Regulation of cancer epigenomes with a histone-binding synthetic transcription factor. / Nyer, David B.; Daer, Rene M.; Vargas, Daniel; Hom, Caroline; Haynes, Karmella.

In: npj Genomic Medicine, Vol. 2, No. 1, 1, 01.12.2017.

Research output: Contribution to journalArticle

Nyer, David B. ; Daer, Rene M. ; Vargas, Daniel ; Hom, Caroline ; Haynes, Karmella. / Regulation of cancer epigenomes with a histone-binding synthetic transcription factor. In: npj Genomic Medicine. 2017 ; Vol. 2, No. 1.
@article{61c0e6e0ed094ac2b7ae21964c40a5bb,
title = "Regulation of cancer epigenomes with a histone-binding synthetic transcription factor",
abstract = "Chromatin proteins have expanded the mammalian synthetic biology toolbox by enabling control of active and silenced states at endogenous genes. Others have reported synthetic proteins that bind DNA and regulate genes by altering chromatin marks, such as histone modifications. Previously, we reported the first synthetic transcriptional activator, the {"}Polycomb-based transcription factor{"} (PcTF) that reads histone modifications through a protein-protein interaction between the polycomb chromodomain motif and trimethylated lysine 27 of histone H3 (H3K27me3). Here, we describe the genome-wide behavior of the polycomb-based transcription factor fusion protein. Transcriptome and chromatin profiling revealed several polycomb-based transcription factor-sensitive promoter regions marked by distal H3K27me3 and proximal fusion protein binding. These results illuminate a mechanism in which polycomb-based transcription factor interactions bridge epigenomic marks with the transcription initiation complex at target genes. In three cancer-derived human cell lines tested here, some target genes encode developmental regulators and tumor suppressors. Thus, the polycomb-based transcription factor represents a powerful new fusion protein-based method for cancer research and treatment where silencing marks are translated into direct gene activation.",
author = "Nyer, {David B.} and Daer, {Rene M.} and Daniel Vargas and Caroline Hom and Karmella Haynes",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41525-016-0002-3",
language = "English (US)",
volume = "2",
journal = "npj Genomic Medicine",
issn = "2056-7944",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Regulation of cancer epigenomes with a histone-binding synthetic transcription factor

AU - Nyer, David B.

AU - Daer, Rene M.

AU - Vargas, Daniel

AU - Hom, Caroline

AU - Haynes, Karmella

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Chromatin proteins have expanded the mammalian synthetic biology toolbox by enabling control of active and silenced states at endogenous genes. Others have reported synthetic proteins that bind DNA and regulate genes by altering chromatin marks, such as histone modifications. Previously, we reported the first synthetic transcriptional activator, the "Polycomb-based transcription factor" (PcTF) that reads histone modifications through a protein-protein interaction between the polycomb chromodomain motif and trimethylated lysine 27 of histone H3 (H3K27me3). Here, we describe the genome-wide behavior of the polycomb-based transcription factor fusion protein. Transcriptome and chromatin profiling revealed several polycomb-based transcription factor-sensitive promoter regions marked by distal H3K27me3 and proximal fusion protein binding. These results illuminate a mechanism in which polycomb-based transcription factor interactions bridge epigenomic marks with the transcription initiation complex at target genes. In three cancer-derived human cell lines tested here, some target genes encode developmental regulators and tumor suppressors. Thus, the polycomb-based transcription factor represents a powerful new fusion protein-based method for cancer research and treatment where silencing marks are translated into direct gene activation.

AB - Chromatin proteins have expanded the mammalian synthetic biology toolbox by enabling control of active and silenced states at endogenous genes. Others have reported synthetic proteins that bind DNA and regulate genes by altering chromatin marks, such as histone modifications. Previously, we reported the first synthetic transcriptional activator, the "Polycomb-based transcription factor" (PcTF) that reads histone modifications through a protein-protein interaction between the polycomb chromodomain motif and trimethylated lysine 27 of histone H3 (H3K27me3). Here, we describe the genome-wide behavior of the polycomb-based transcription factor fusion protein. Transcriptome and chromatin profiling revealed several polycomb-based transcription factor-sensitive promoter regions marked by distal H3K27me3 and proximal fusion protein binding. These results illuminate a mechanism in which polycomb-based transcription factor interactions bridge epigenomic marks with the transcription initiation complex at target genes. In three cancer-derived human cell lines tested here, some target genes encode developmental regulators and tumor suppressors. Thus, the polycomb-based transcription factor represents a powerful new fusion protein-based method for cancer research and treatment where silencing marks are translated into direct gene activation.

UR - http://www.scopus.com/inward/record.url?scp=85026449430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026449430&partnerID=8YFLogxK

U2 - 10.1038/s41525-016-0002-3

DO - 10.1038/s41525-016-0002-3

M3 - Article

AN - SCOPUS:85026449430

VL - 2

JO - npj Genomic Medicine

JF - npj Genomic Medicine

SN - 2056-7944

IS - 1

M1 - 1

ER -